Navigation path

Additional tools

    Profile of registrant

Eli Lilly and Company

Identification number in the register: 04657143399-39
Registration date: 02/04/2010 15:17:43

The information on this entity was last modified on: 18/11/2016 11:21:28
The date of the last annual update was: 18/04/2016 11:32:37
Next update due latest on: 18/04/2017

    Registrant : Organisation or self-employed individual

Eli Lilly and Company



    Section of registration

II - In-house lobbyists and trade/business/professional associations

Companies & groups

    Contact details

Lilly Corporate Centre, 1
Indianapolis 46285


Rue du Marquis 1
Brussels B-1000


    Person with legal responsibility

Mr  John Lechleiter

Chairman and CEO

    Person in charge of EU relations

Mr  Thomas Thorp

Senior Director Corporate Affairs and Market Access

    Goals / remit

Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Headquartered in the US, Lilly has approximately 41.000 employees worldwide with approximately 9.000 based in Europe. In 2015 global revenue was approx. $19.96 billion, of which 24% were invested in R&D.

( )

Elanco is the animal health business unit of Lilly. Elanco is an innovation-based company which makes life sciences work better for people by transforming animal protein production and companion animal care. Elanco operates in more than 75 countries worldwide, focusing on products for companion animal and food animal health, vaccines, parasiticides, enzymes, diagnostics and aquaculture.

Both are part of Lilly as a single legal entity.


    Specific activities covered by the Register

Human and animal healthcare legislation; Intellectual Property; European Medicines Agency; Data Privacy, Clinical Trials Transparency; Health Technology Assessment including EUnetHTA; Transparency Directive; Falsified Medicines Directive; Trade including TTIP; Industrial policy; Competition; Taxation; Environment including REACh; Innovative Medicines Initiative

None foreseen







Clinical Trials Directive, trade, intellectual property, EU 2020, Innovation Union, pharmaceuticals, healthcare, global health, innovation and research, veterinary medicine, business competitiveness, common agricultural policy, industrial policy.

    Number of persons involved in the activities described in the box above

50%: 3   25%: 1



Note: 2 colleagues are full-time engaged in the Brussels office, and 1 outside Brussels, and will spend approx 25% - 50% of their time on relevant EU affairs. A few other colleagues whereas spend a fraction of their time (0-5%).

    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Aoife GALLAGHER 22/11/2016 18/11/2017
Elisa Irlandese 15/09/2016 13/09/2017
Doris SCHERNHAMMER 22/11/2016 18/11/2017
Sonia Ujupan 16/11/2016 14/11/2017

    Fields of interest

  • Agriculture and Rural Development
  • Competition
  • Customs
  • Economic and Financial Affairs
  • Employment and Social Affairs
  • Energy
  • Enterprise
  • Environment
  • External Relations
  • Fisheries and Aquaculture
  • Food Safety
  • General and Institutional Affairs
  • Internal Market
  • Public Health
  • Research and Technology
  • Taxation
  • Trade

    Membership and affiliation

Eli Lilly and Company is a member of the following associations and bodies: EFPIA, EuropaBio, AmChamEU, the British Chamber of Commerce to the EU, US Chamber of Commerce, Trans-Atlantic Business Council, American European Community Association, Trade Policy Network, EAASM, ASOP EU, IFAH-Europe, FEFAC.

    Financial data

01/2015  -  12/2015

700,000 € - 799,999 €

No funding received from the EU institutions during the last closed financial year.

This estimate is calculated according to pro rata staffing and office costs of Eli Lilly and Company staff involved in interest representation towards the European institutions as defined under the Register, based on the proportion of employee time devoted to these activities. In accordance with the Transparency Register Compliance guidelines on financial information, this estimate of costs as a range includes fees paid for outsourced activities (i.e consultancy contract fees). The estimate includes relevant membership fees to the various trade associations and other bodies. The list is included in the membership section of this form.

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code:
EFPIA Codes - and the Eli Lilly Code of Conduct ("The Red Book-Code of Business Conduct")